Opus Genetics to Present at OIS Retina Innovation Summit 2022
July 11, 2022 07:30 ET
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Ben...
Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
June 21, 2022 07:30 ET
|
Opus Genetics
Industry veteran and experienced CEO will continue to lead the company as its AAV-based gene therapies for inherited retinal diseases approach the clinic RESEARCH TRIANGLE PARK, N.C., June 21, 2022 ...
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
May 11, 2022 08:00 ET
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced the...
Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
May 04, 2022 16:05 ET
|
Opus Genetics
Retinal regions of preserved photoreceptors identified as targets for subretinal delivery of AAV8-based gene therapy to address mutations in genes that cause forms of Leber congenital amaurosis ...
New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
April 28, 2022 08:00 ET
|
Opus Genetics
RALEIGH, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced that data from two...
Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases
April 11, 2022 08:00 ET
|
Opus Genetics
RALEIGH, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced a strategic...
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
February 15, 2022 07:30 ET
|
Opus Genetics
RALEIGH, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced the appointment of...
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
November 11, 2021 10:36 ET
|
Opus Genetics
RALEIGH, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced an agreement to...
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
November 08, 2021 08:30 ET
|
Opus Genetics
RALEIGH, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced that Ben Yerxa,...
Opus Genetics Announces Two Key Leadership Appointments
October 20, 2021 07:30 ET
|
Opus Genetics
Dr. Ash Jayagopal named Chief Scientific OfficerMr. Joe Schachle appointed Chief Operating Officer RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy...